



CIO Office Global Markets Weekly Kickstart

Pharma Protectionism in Progress


20 April 2026

01 CIO Insights

Consolidation of a US-centric Investment Portfolio

02 Chart of the Week

TSMC Earnings Beat Expectations,
Bullish Long-Term Outlook for Taiwan
Supply Chain



03 Market Recap

Markets Rally on Potential Ceasefire,
Sentiment Shifts from Conservative to
Proactive



04 What's Trending

Investment Opportunities in US-Iran
Conflicts through the Lens of Trump's
First Term



05 In Focus

Trump Initiates Section 232 Tariffs on
Pharmaceuticals, Benefiting US
Drugmakers



06 Product Spotlight

Selection of Equities, Bonds and Funds/ETFs

Consolidation of a US-Centric Investment Portfolio

► Passed the Peak of Fear Does Not Mean Risk Came Down


The market is reacting calmly to the development of the war in Iran. The whipsaw of the sentiment becoming less of a market driver. Despite the short-term normalization of the fear index, three things will remain the same even after the war ends: 1) fear of inflationary pressure will keep the rates at slightly restrictive; 2) worsening debt situation of the US will keep long rates elevated; 3) sporadic domestic and foreign policies of the US administration will keep the risk premium high. In short, the discount rate for the equities will remain elevated.

► Consolidation of a Us-Centric Investment Portfolio

Elevated risk premium is unfavorable to valuation. We like selective growth/AI stocks but will recommend an expansion to value stocks in other traditional industry such as consumer staples, healthcare, utilities (excluding electric utilities), and telecommunications, as well as companies with high ROE, stable earnings, low leverage, and consistent cash flow. On fixed income, we prefer IG corporate credit because of their significant better balance sheets than the US government.



CBOE VIX index – Every President Has His Moment Donald Trump Does Not Drive Excessive Market Volatility

(Index)



TSMC Earnings Hit Record Highs; Chairman Emphasizes "Insatiable AI Demand"

- ▶ TSMC announced its 1Q26 results, with revenue reaching NT\$1.134 trillion, exceeding market expectations of NT\$1.127 trillion. Net income stood at NT\$572.48 billion, also beating the consensus of NT\$543.32 billion. Driven by high-margin AI revenue, the gross margin reached a new record of over 66%, with a net profit margin of 50.5%. 1Q EPS simultaneously hit an all-time high of NT\$22.08.
- ▶ By product segment, High-Performance Computing (HPC), primarily fueled by AI, saw robust growth with a 20% QoQ increase. This pushed HPC's revenue contribution above the 60% threshold for the first time. Conversely, smartphone demand remained sluggish, declining 11% QoQ.
- ▶ During the earnings call Q&A, Chairman C.C. Wei noted that all customers are signaling an urgent need for capacity. To meet this demand, TSMC must accelerate its expansion roadmap, working closely with construction contractors and equipment suppliers to pull forward expansion schedules. He emphasized that AI demand is exceptionally strong. This robust demand is expected to bolster the revenue performance of the Taiwan-based supply chain, particularly in the aforementioned sectors, which may preemptively reflect this optimistic sentiment.




Source: TSMC Earnings, KGI

Market Recap


US-Iran Negotiations Progress Smoothly; Risk Appetite Surges as Industry Styles Shift

- ▶ Despite the impending expiration of the two-week ceasefire agreement between the U.S. and Iran and the lack of a scheduled second round of talks, Trump stated that Iran is interested in reaching a deal and that negotiations are progressing smoothly. This week, markets reflected optimism over the increased probability of peace talks. Global risk sentiment improved significantly, with capital flowing back into risk assets. All four major U.S. indices closed in the green, led by the Philadelphia Semiconductor Index (SOX) with a weekly gain of 7.4%. European markets, which were less impacted by the US-Iran conflict previously, showed relatively weaker gains this week. In contrast, Asia and emerging markets benefited significantly from the improved risk appetite. The Nikkei 225 performed strongly with a 4.2% weekly gain, making it one of the top performers among major markets outside the U.S.
- ▶ In terms of industry sectors, a clear divergence in styles was observed. Responding to the "risk-on" atmosphere, the market aggressively shifted from defensive sectors to cyclical stocks. Healthcare, consumer staples, and utilities performed poorly, while cyclical and growth sectors—such as information technology, consumer discretionary, and communication services—saw significant gains.

Regional Index Performance (%)




U.S. Sector Index Performance (%)



HY Bonds Gain on Risk-On Sentiment; Weaker Dollar Lifts Emerging Debt and Crypto

- ▶ Despite energy prices recording their largest gains since 2005, March inflation and core inflation data came in lower than expected. The U.S. March CPI rose 3.3% YoY, below the market expectation of 3.4% but a significant jump from 2.4% in February; core CPI rose 2.6% YoY, lower than the 2.7% forecast. Inflation data is expected to be impacted by high oil price spillovers, thereby limiting the room for rate cuts before year-end. KGI Invest believes the inflation risk is a one-off impact and the Fed will maintain its current monetary policy path. If oil prices retreat, the Fed may not resume rate cuts until the first half of 2027; Treasury yields remained stable.
- ▶ However, the strong atmosphere surrounding a potential U.S.-Iran agreement has improved risk sentiment, driving significant gains in both Investment-Grade (IG) and High-Yield (HY) bonds. The anticipated decline in oil prices is expected to ease operating costs for lower-rated companies, leading to a more pronounced narrowing of credit spreads in high-yield bonds.
- ▶ The U.S. Dollar retreated due to the optimistic market mood, leading to notable gains in emerging market debt. Precious metals like silver and risk assets such as cryptocurrencies also benefited, showing a clear price rebound. In terms of commodity performance this week, only crude oil prices fell back as geopolitical risks subsided.



Source: Bloomberg


For Internal Use Only

6


Trump's First Term vs. Current Term: Investment Opportunities Amid US-Iran Tensions

- ▶ Across both terms, Trump targeted Iran in his second year in office, with the core objective of preventing Iran from acquiring nuclear weapons. His first term relied primarily on economic sanctions paired with limited military actions. In contrast, the current term has shifted toward large-scale military operations, including the elimination of Iran's supreme leader and senior officials. During the first term, conflicts persisted until the 2020 pandemic, though their market and economic impact eventually diminished, with inflation receding from peaks before the midterm elections.
- ▶ The current term has seen a more severe oil price shock. Even if the impact on prices is a one-off event, inflation may remain elevated for an extended period, delaying the Federal Reserve's rate-cut plans. While the U.S. 2-year Treasury yield has retreated from its highs, it remains above pre-conflict levels. According to FedWatch, the probability of a single rate cut for the entire year has dwindled to approximately 30%.
- ▶ Midterm elections typically favor stock market performance, and Trump likely aims to prevent the conflict from hindering the Republican Party's electoral prospects. However, rising risk-free rates have pushed up discount rates, exerting pressure on stock valuations. Moving forward, a more rational approach to valuations is advised; portfolios should not be solely concentrated in high-valuation, high-growth enterprises.

Comparing Trump's Two Terms on Iran Strategy



Improved Investment Sentiment ,but Diminished Rate-Cut Prospects




Global Pharma Giants Reach Accords with Trump to Avert 100% Tariff Crisis

- ▶ In April 2026, Trump signed an executive order under Section 232 to impose a 100% tariff on imported patented drugs and key active ingredients. The policy utilizes a tiered tax structure aimed at lowering domestic drug prices and forcing supply chains back to the U.S. For individual companies, drugmakers can secure a 0% tariff until 2029 by agreeing to Most-Favored-Nation (MFN) pricing and signing reshoring agreements. Those committing to relocate production bases to the U.S. can receive an initial 20% preferential rate until 2030. At the national level, specific import exemptions have been established: 10% for the UK, and 15% for the EU, Switzerland, Japan, South Korea, and Liechtenstein. Currently, most major pharmaceutical exporters to the U.S. (by value)—with the exceptions of India and China—have reached preferential rate agreements with the Trump administration.
- ▶ Regarding individual firms, nine of the world’s top ten pharmaceutical companies by market capitalization are listed in the U.S. To proactively comply with policy, these giants have successively reached agreements on MFN pricing (offering the lowest global prices within the U.S.) and domestic investment commitments in exchange for tariff exemptions.

Major Pharmaceutical Importers to the U.S.

U.S. Drug Import Share by Country of Origin (%)



Global Pharma Giants' Agreements with Trump for 3-Year Tariff Exemptions


Company	Ticker	Agreement Details & Investment Commitment
Eli Lilly	LLY	Significantly lower GLP-1 (weight loss/diabetes) prices; expand U.S. domestic capacity.
Novo Nordisk	NVO	Lower prices for Wegovy and insulin; ensure U.S. supply chain resilience.
Johnson & Johnson	JNJ	Signed MFN pricing agreement to ensure U.S. prices do not exceed global lows.
Merck	MRK	Adopt MFN pricing for cancer and chronic disease medications.
AbbVie	ABBV	Price reduction for immunology drugs; evaluate increasing U.S. API (Active Pharmaceutical Ingredient) production.
Novartis	NVS	High discounts for specific prescription drugs; adopt MFN pricing.
AstraZeneca	AZN	Historic price cuts for respiratory and cancer drugs; commit to increased U.S. R&D investment.
Roche	N.A.	Adopt MFN pricing; reform pricing models for high-cost ophthalmology and oncology biologics.
Pfizer	PFE	Comprehensive MFN pricing; commit to US\$70 billion in additional U.S. R&D and CAPEX.
Amgen	AMGN	Partial MFN pricing; peg specific biologic prices to international lows.

Source: Bloomberg, KGI


U.S. Drug Manufacturing Surges Under Trump; Markets Pivot Back to Biopharma

- ▶ During his first term, Trump actively promoted the reshoring of pharmaceutical manufacturing to fulfill his "America First" agenda. Amidst the COVID-19 pandemic, an executive order required federal agencies to prioritize the procurement of essential medicines and key active ingredients produced domestically. His second term has intensified these efforts through Section 232, leading to a marked increase in branded drugs manufactured in the U.S. in both periods. In 2025, production volume grew by approximately 4.8% YoY; as of March 31, 2026, the number of U.S.-made branded drugs has surpassed 2,600 units, representing a 3.4% growth compared to year-end.
- ▶ Under the pressure of Trump's Section 232 tariff threats, pharmaceutical giants have redirected capital expenditures and R&D toward the U.S. This shift has reignited market interest in domestic biopharmaceutical equity investments. Compared to the same period last year, U.S. venture capital and private equity (VC/PE) funding has grown by 26%. The capital raised through biopharma IPOs and follow-on offerings has seen even more significant growth, reaching US\$11.8 billion as of March 31, 2026—a 153% YoY increase. This indicates that capital is aggressively positioning itself during the recent market correction. With the Section 232 tariff conditions now finalized, the biopharma sector is poised to reflect potential growth opportunities driven by the reshoring of investment to the U.S.

Significant Rise in U.S.-Manufactured Branded Drugs During Trump Administrations



Surge in Market Interest for U.S.-Listed Biopharmaceutical Companies



Source: ibisworld (left axis), UBS (right axis), data as of March 31, 2026, KGI

Asset Strategy

Asset Type	Market View	Preferred Assets
Equities	<ul style="list-style-type: none"> ◆ Markets are reflecting a potential U.S.-Iran ceasefire, leading to a retreat in oil prices and slightly lower inflation expectations. However, risks such as rising production costs and equity valuation adjustments remain; U.S. equities are expected to experience continued volatility. Given current economic uncertainty and heightened fluctuations, defensive, low-volatility, and high-quality stocks are recommended as top picks, such as Consumer Staples, Healthcare, Utilities, and Telecommunications. Re-entry into AI themes like Technology, Communication Services, Consumer Discretionary, and Industrials is suggested for the latter half of Q2. ◆ European and Japanese equities can serve as key diversification anchors, with Japanese stocks showing higher upside potential than European ones. Japanese holdings should focus on Value and Banking stocks, while also monitoring commercial and wholesale companies with the HALO theme. The Eurozone reflects geopolitical pricing, with Defense as a primary support, specifically in Germany and the UK. 	<p>Strategy: Core allocation in large-cap high-quality and defensive stocks (Telecommunications, Utilities). Long-term positioning in AI themes (Technology, Semiconductors, Machinery). Non-AI convictions include Aerospace, Defense, and Value stocks.</p> <p>Regions: Japanese Banks, Japanese Semiconductors, German equities, and UK equities.</p>
Bonds	<ul style="list-style-type: none"> ◆ Fed minutes show that rate hikes to counter inflation from Middle East conflicts are not ruled out. The Fed is expected to maintain current monetary policy to observe data trends. Before oil prices and geopolitical risks subside, and with expanding U.S. government spending, Q2 U.S. Treasury yields may trend upward. High-quality corporate bonds offer better credit health and defensive capabilities; investors can utilize rate spikes to position in intermediate-term bonds, focusing on attractive risk-adjusted spreads in the Financial, Communication, Utility, and Energy sectors. ◆ The USD is strong in the short term but faces long-term depreciation concerns. Non-USD bonds, such as EUR and AUD-denominated investment-grade bonds, can be added to diversify risk. 	<p>Types: Lock in yields with intermediate-term high-quality bonds; sectors include Financials, Communications, Utilities, and Energy.</p> <p>Satellite Allocation: Non-USD bonds for risk diversification.</p>
Forex	<ul style="list-style-type: none"> ◆ Geopolitical disturbances have cooled slightly, curbing oil prices. Major central banks remain in a wait-and-see mode. The USD has retreated in the short term but remains bearish in the mid-to-long term. ◆ With the USD consolidating at highs in Q2, the RMB is expected to show relative strength. 	<p>USD: USD retreating short-term, bearish mid-to-long term with limited downside.</p> <p>EUR/JPY range-bound, RMB biased toward appreciation.</p>
Commodity	<ul style="list-style-type: none"> ◆ Gold has rebounded recently due to the decline in the USD and Treasury yields. Geopolitical risks from Trump, the scramble for critical resources, and market uncertainty from tariffs maintain gold's allocation value. We hold a bullish mid-to-long-term outlook and recommend accumulating on significant pullbacks. 	<p>Gold: Bullish mid-to-long term; accumulate on significant pullbacks.</p>

► Increased AI Investment Triggers Market Concerns

Initial market worries regarding AI investment primarily centered on short-term margin erosion, uncertain payback periods, and cost pressures driven by geopolitics. Investors were concerned that massive spending on computing power would crowd out share buybacks and dividends. However, as AI demonstrates "cost reduction and efficiency enhancement" in precision advertising and cloud services, the market is gradually recognizing its technological barriers. AI expenditure should be viewed as a necessary requirement for maintaining long-term competitiveness rather than a mere spending burden.

► China's Interest Rate Trends Amid High Oil Prices and Inflation

While the world faces high-interest rate pressures due to oil price volatility, China is exhibiting a distinct policy cycle. Benefiting from a low inflation base, there is no domestic pressure to hike rates; meanwhile, the PBoC prioritizes exchange rate stability, and interest rate policy is expected to remain "structurally stable." Unlike overseas markets, a moderate recovery in inflation is actually conducive to repairing corporate pricing power. In an environment of sideways interest rates and improving fundamentals, Tencent and Alibaba—with their strong cash flows—offer significantly better asset value than industries heavily reliant on debt expansion.

► Rationality of Current Valuations Exceeding Post-COVID Levels

The current recovery in valuations is highly rational. Previous low valuations stemmed from extreme panic over regulation and the real estate crisis, whereas current policy has clearly shifted toward supporting the platform economy, significantly reducing risk premiums. Supported by EPS growth recovery and large-scale share buybacks, current stock prices reflect a return from "crisis mode" to "normal growth mode." Compared to U.S. tech giants, China Concept Stocks still offer significant value.

Source: Bloomberg

China CPI YoY Growth vs. 10-Year Treasury Yield



Inflation YoY % (Orange),
10-Year Government Bond Yield (Blue)

Tencent (700)

Closing Price HK \$515.5

Target Price HK \$700

Primarily provides value-added services (VAS), online advertising services, as well as fintech and business services.

AI Investment Increase Has Limited Impact on Free Cash Flow (FCF)

This year's R&D expenditure on AI is expected to double compared to 2025. However, this level of spending has a limited impact on FCF. Assuming FCF remains consistent with the same period last year, the new investment accounts for only 10% of FCF, while funds used for dividends and debt repayment account for approximately 30%. This indicates that management still has substantial capital available for share buybacks. Nevertheless, a more conservative buyback plan—expected to be lower than last year's level—has weighed on stock performance. In reality, AI efficiency is already manifesting; the market should shift its focus from the "amount of capital expenditure" to the "AI-driven Long-term Return on Investment (ROI)."

Continued Improvement in AI-Enabled Benefits



Past AI investments have demonstrated effectiveness across various segments. For instance, precision advertising has improved click-through rates, and the integration of AI in the gaming business has shortened development times and reduced costs. The efficiency gains from AI are reflected in margins: from 2023 to 2025, gross margin rose from 48% to 56%, while profit margin increased from 25.9% to 34.5%, both signaling enhanced operational efficiency. Furthermore, management plans to promote "tokenization" to boost commercialization effectiveness and overall profitability.

Current Valuation Offers Better Entry Point

Market concerns over increased AI spending impacting investment efficiency and the reduction in buyback scale are overblown. Tencent's valuation has dropped to a forward P/E of 14x, a multi-year low, providing a better entry point for investors. Investors should continue to monitor Tencent's AI developments and the grossing performance of new game modes for its evergreen IP, Honor of Kings. We maintain a target price of HKD 700.

Source: Bloomberg

Financials					
	2023	2024	2025	2026F	2027F
Revenue (CNY b)	609	660	751	830	914
Revenue YoY	9.8	8.4	13.8	10.5	10.0
EPS (CNY)	16.3	23.5	27.8	30.6	34.3
EPS YoY	37.8	44.0	18.6	9.8	11.9
ROE(%)	15.1	21.8	21.1	19.7	18.9



For Internal Use Only

Alibaba (9988)

Closing Price HK \$136.9

Target Price HK \$165

The company provides technological infrastructure and marketing platforms that enable merchants, brands, retailers, and other businesses to leverage new technologies to engage with users and customers while operating more efficiently.

Three-Digit Growth in AI Tools; Cloud Business Commands Pricing Power and Market Share

Benefiting from the AI wave, the token consumption of the "Model Studio" (MaaS platform) surged sixfold YoY. This reflects strong corporate demand for large language models like Tongyi Qianwen, further accelerating the sequential growth rate of external cloud revenue. Amid tight computing power supply, the company has demonstrated pricing power, recently raising prices for certain cloud products by over 30%. Combined with the large-scale deployment of self-developed T-Head chips, the company ensures supply while significantly reducing inference costs. The cloud business is shifting from traditional resource sales to high-margin "Intelligent Services." Management aims for the AI business to reach US\$100 billion within five years, implying a segment revenue CAGR of 40% and positioning it as a key engine for non-linear growth.

Path to Profitability in Instant Retail Eases Negative Pressure



Although losses in instant retail (e.g., flash sales, Ele.me) were higher than expected in the third fiscal quarter, management has provided a clear roadmap. The goal is to achieve over RMB 1 trillion in GMV by FY2028 and reach profitability by FY2029, which helps eliminate expectations of further expanding negative impacts. The business is shifting from scale expansion to optimizing Unit Economics (UE), with losses expected to narrow. This will alleviate overall margin pressure and support the recovery of the bottom line. Simultaneously, instant retail creates strong synergies with the core e-commerce business by introducing new users and increasing consumption frequency.

Negative Factors Largely Priced In

The market has largely digested the negative impact of the instant retail segment, and the stock price performance has not lagged behind the Hang Seng Tech Index. However, due to the impact of instant retail losses, the target price has been adjusted to HKD 165.

Source: Bloomberg

Financials					
	2023	2024	2025	2026F	2027F
Revenue (CNY b)	868	941	996	1026	1141
Revenue YoY	1.8	8.3	5.9	3.1	11.1
EPS (CNY)	6.8	7.8	8.2	3.9	6.3
EPS YoY	3.5	14.1	5.1	-52	60.7
ROE(%)	7.5	8.1	12.9	7.5	9.3



For Internal Use Only



U.S.-Iran Conflict Subsides; Markets Pivot to New Narratives

- ▶ U.S. March Core PPI increased 0.1% MoM, lower than the previously revised 0.3% and below the market expectation of 0.4%. On a YoY basis, Core PPI rose 3.8%, remaining flat compared to the revised previous figure and coming in below the anticipated 4.1%.
- ▶ U.S. equities staged a V-shaped recovery in early April, reaching new all-time highs. The rally was primarily led by the Semiconductor and Technology sectors. The market narrative has swiftly shifted from the U.S.-Iran conflict back to the AI theme. On the policy front, the U.S. government has initiated a Section 232 investigation into imported patented drugs and their raw materials, imposing a 100% punitive tariff. If implemented, this tariff could provide a significant tailwind for U.S. pharmaceutical companies. As a defensive sector with currently attractive valuations, we recommend that investors consider strategic allocations to the U.S. Healthcare sector.

S&P 500 Healthcare Index Forward P/E Ratio



Source: Bloomberg

For Internal Use Only

14

Merck & Co., Inc. (MRK)

Closing Price US \$119.07

Target Price US \$132

Merck & Co. is a global healthcare company providing health solutions through prescription medicines, vaccines, biologic therapies, animal health, and consumer products. These products are distributed via direct sales and joint ventures. The company operates across the pharmaceutical, animal health, and consumer healthcare sectors.

Keytruda Continues to Bolster Earnings; FY26 as a Transitional Phase

Keytruda remains the company's core profit driver, generating US\$31.7B in revenue in FY25, accounting for ~48.7% of total revenue. Ahead of its patent expiration in 2028, it continues to benefit from new indications and the launch of the subcutaneous version, Keytruda Qlex. However, despite a strong 4Q, FY26 revenue guidance was set at US\$65.5B–\$67B, missing market expectations due to generic competition, Medicare price negotiations, and weakening COVID-19 treatment demand. The company is entering a short-term transitional phase awaiting new growth momentum.

Proactive Response to Patent Cliffs and Tariff Risks

Merck is mitigating the 2028 patent cliff by filing supplementary patents and strengthening Keytruda's lifecycle management. Simultaneously, the company is advancing its U.S. localization to reduce policy and supply chain risks. In 2025, Merck announced plans to invest over US\$70B in the U.S., helping buffer the impact of potential "100% tariffs on patented drugs" and providing an advantage to firms committed to domestic production.

4Q25 Results Exceed Expectations

4Q revenue grew 5% YoY to US\$16.4B, with adjusted EPS of US\$2.04—both beating consensus. Performance was driven by Keytruda's US\$8.87B in quarterly sales. Although management anticipates a US\$2.5B headwind in FY26 from loss of exclusivity (LOE) on older products and Medicare/IRA pricing pressures, they still expect long-term revenue growth of 5%–8%.

Valuation Consensus

The Bloomberg 12-month average target price is US\$132.11, with a high of US\$150 and a low of US\$100.

Source: Bloomberg, Company 10K

1-Year Price

(USD)



Historical Product Sales

(\$ in millions)	2025	2024	2023
Total Sales	\$ 65,011	\$ 64,168	\$ 60,115
Pharmaceutical	58,142	57,400	53,583
Keytruda/Keytruda Qlex	31,680	29,482	25,011
Gardasil/Gardasil 9	5,233	8,583	8,886
Januvia/Janumet	2,544	2,268	3,366
ProQuad/M-M-R II/Varivax	2,451	2,485	2,368
Bridion	1,841	1,764	1,842
Alliance revenue - Lynparza ⁽¹⁾	1,450	1,311	1,199
Winreva ⁽¹⁾	1,443	419	—
Alliance revenue - Lenvima ⁽¹⁾	1,053	1,010	960
Prevymis	978	785	605
Vaxneuvance	825	808	665
Capvaxive	759	97	—
Wellireg	716	509	218
Animal Health	6,354	5,877	5,625
Livestock	3,896	3,462	3,337
Companion Animal	2,458	2,415	2,288
Other Revenues ⁽²⁾	515	891	907

Financials

	2023	2024	2025	2026F	2027F
Revenue Growth(%)	1.4	6.7	1.3	2.6	5.2
EBITDA (%)	46.3	40.0	46.4	30.3	45.7
EPS(USD)	6.76	7.00	8.04	5.11	9.68
Net Profit Margin(%)	28.6	27.7	31.0	18.9	33.8

Source: Bloomberg; 2027/28F are market estimates

P/E & P/B





Taiwan Equities Hit New Record Highs; Persistent Memory Price Hikes Sustain Sector Momentum

TSMC Hits Record Price, Pushing TAIEX to All-Time Highs

Observing the market structure last week, TSMC reached a new price peak while large-cap electronics generally maintained strength or continued to rally, favoring further record highs for the TAIEX. Individual sectors focusing on optical communications, GaAs, CCL, thermal management, Design IP, and semiconductor testing interfaces remain in the spotlight. Non-electronics sectors are seeing laggard rallies, with only Formosa Plastics Group stocks worth noting. If the rally continues short-term, investors should guard against volatility after extended gains. However, with recent volume and price controlled well, downside is expected to be limited. The bullish trend remains intact as long as the support at the previous high of 35,579 holds.


DDR4 Supply-Demand Tightness Shows No Signs of Reversal; Prices Surging

According to KGI Invest supply chain surveys, DDR4 supply growth for 2026–2027 is limited: (1) PSMC’s P3 fab capacity for 2027 is only ~20k; (2) Nanya Tech’s Fab 5A will primarily produce DDR5 and LPDDR5/5x, while Winbond’s Kaohsiung 16nm capacity will focus on DDR4, LPDDR4x, and CUBE. If DDR4 supply-demand eventually loosens, Nanya Tech and Winbond have the flexibility to shift 1Bnm and 16nm capacity toward DDR5 and CUBE, respectively. Regarding pricing, March DDR4 8Gb contract prices rose to US\$15–\$18; we forecast a 40–50% QoQ increase in 2Q26 to US\$22–\$25, potentially reaching US\$30 in 2H26.


Clear Catalysts for Memory Stocks: (1) Nanya Tech: Its Mar 25 private placement announcement introduced strategic investors like SanDisk, Kioxia, and Solidigm. Beyond funding 2026 CAPEX, this highlights the persistent shortage of DDR4/LPDDR4/4x and aids future DDR5/LPDDR5/5x order expansion. (2) Macronix: Supply chain surveys indicate its eMMC pricing will shift from quarterly to monthly in April. 4GB prices are expected to jump 180–200%, while 8GB prices may rise 50–60%. KGI Invest is bullish on the company benefiting from structural eMMC shortages, marking the start of a long-term profit cycle.

Source: Bloomberg

TAIEX Index and Taiwan Electronics Sector Trends



DDR4 8Gb Contract Price



Macronix International Co., Ltd. (2337.TT)

Macronix is a manufacturer of memory products including ROM, NOR Flash, and NAND Flash. The company also operates logic IC foundry services, with production facilities including the 12-inch Fab 5 and the 8-inch Fab 2.

Key Features


Low-Capacity eMMC: The Sole Supplier After 2028

NAND Flash technology has evolved rapidly in recent years. Due to the low unit value of MLC (Multi-Level Cell), which lacks the economies of scale sought by major manufacturers, global leaders are concentrating resources on TLC, QLC, and DRAM, subsequently announcing EOL (End of Life) for MLC products. Samsung, Micron, Kioxia, and SK Hynix are set to phase out production between 2026 and 2027, leaving Macronix as the world's only MLC supplier after 2028. Overall, global MLC bit supply is projected to plummet from 91.77B Gb in 2025 to 36.49B Gb in 2028, with YoY growth rates of -51% in 2026, -30% in 2027, and +17% in 2028.

Entering a Long-term Profit Cycle

Macronix's eMMC bit shipments are projected to account for only ~25% of total eMMC demand in 2027, indicating significant growth potential. Supported by the long-tail demand for low-capacity eMMC in automotive, drone, industrial control, and networking applications, we believe Macronix will maintain stable profitability over the coming years.

Revenue Sources and Regions




Source: Bloomberg

Financials


	2023	2024	2025F	2026F	2027F
EPS (NTD)	-0.92	-1.73	-1.77	30.04	107.25
EPS Growth (%)	-118.9	89.1	2.1	0.0	257.0
P/E Ratio	NA	NA	NA	3.3	0.9
ROE (%)	-3.4	-7.0	-7.4	75.6	103.0

Source: Company data, estimates of KGI analyst

Valuations



1-Year Price



As of 16 Apr 2026	1Wk	1M	3M	6M	YTD	1Y
Return (%)	-2.11	16.81	107.46	414.81	252.34	623.96

Nanya Technology Corp. (2408.TT)

Nanya Technology Corp. manufactures and distributes semiconductor products (DRAMs). In addition to domestic sales in Taiwan, the company exports its products to markets worldwide.

Key Features


Strong 1Q26 Results

Revenue reached NT\$49.1B, up 582.9% YoY, driven by a QoQ ASP increase of over 70%. Gross margin rose 18.9 percentage points QoQ to 67.9%, slightly below the estimated 68.7%. Supported by NT\$1.61B in non-operating income, net income reached NT\$26.1B, up 134.9% QoQ. EPS stood at NT\$8.41, beating KGI Invest's estimate of NT\$8.07.

Earnings Momentum Continues Upward

For 2Q26, management expects contract prices to maintain significant upward momentum, potentially rising by double-digit percentages QoQ, further boosting gross margins. We estimate DDR4 8Gb prices will rise 64%, 22%, and 14% QoQ from 2Q26 to 4Q26, respectively. The company plans to mass-produce DDR4 16/32Gb and high-frequency DDR5 in 4Q26 and 2Q27, entering the high-premium RDIMM market. Overall, rising memory prices, customer base transformation, and product mix upgrades will drive further earnings upward revisions.

Revenue Sources and Regions




Source: Bloomberg

Financials


	2023	2024	2025	2026F	2027F
EPS (NTD)	-2.40	-1.64	2.13	36.22	44.81
EPS Growth (%)	-150.9	-31.7	0.0	1,596	23.7
P/E Ratio	NA	NA	96.0	5.7	4.6
ROE (%)	-4.3	-3.1	3.9	54.3	43.5

Source: Company data, estimates of KGI analyst

Valuations



1-Year Price



As of 16 Apr 2026	1Wk	1M	3M	6M	YTD	1Y
Return (%)	4.15	-18.36	-14.60	124.97	10.62	551.91

Multi-Asset Portfolio Reduces High-Valuation Equity Exposure While Holding High-Quality Credit Bonds

► KGI Diversified Growth & Income Fund

- **Strategic Collaboration:** Combines the strengths of KGI Group and renowned asset manager Loomis Sayles to enhance asset allocation precision and strengthen short-term volatility management. Established in 1926, Loomis Sayles identifies long-term value opportunities through deep research and risk control, managing US\$425.5B in assets.
- **Balanced Strategy:** Pursues returns through growth stocks and high-yield bonds while mitigating downside risk with investment-grade bonds and equity options.
- **Dynamic Adjustments:** Captures opportunities while reducing risk via active rebalancing. For instance, in early 2025, the fund proactively reduced equity exposure and increased cash to avoid U.S. market downturns, subsequently adding to Tech, non-U.S. markets, and Gold ETFs to capture rallies.
- **Strong Performance:** Since its inception in late Nov 2019, this multi-asset strategy has outperformed peers through various market cycles.
- **Structure:** Public fund under the Hong Kong OFC framework; CIES (Capital Investment Entrant Scheme) eligible.
- **Distribution:** Monthly dividend payout with a target annualized yield of 8%.

Product	KGI Diversified Growth & Income Fund	
Features	<ul style="list-style-type: none"> ■ Adopts a global multi-asset allocation to balance growth and defense, seeking returns via large-cap growth stocks and high-yield bonds while enhancing protection with investment-grade bonds and options. ■ Leverages the combined expertise of KGI Group and renowned asset manager Loomis Sayles to improve asset allocation precision and strengthen short-term volatility management. 	
Currency	USD	
3M/YTD Return	- / 8.17%	
Top 5 Sector Allocation (%)	Information Technology	22.3
	Communication Services	16.1
	Consumer Discretionary	8.9
	Energy	6.9
	Industrials	6.8
Top 5 Asset Allocation (%)	Equities	55.5
	Non-IG Bonds	17.9
	IG Bonds	20.0
	Derivatives & Others	6.6
Top 5 Holdings (%)	Apple Inc.	3.3
	NVIDIA Corp.	3.1
	iShares 0-5 Year Investment Grade Corporate Bond ETF	3.0
	Microsoft Corp.	3.0
	Amazon.com, Inc.	2.9

Source: Bloomberg

KGI Diversified Growth & Income Fund

Profile

The fund invests at least 70% of its net asset value (NAV) directly or indirectly in global assets, including equity and equity-related securities (such as stocks, preferred stocks, and depository receipts) and debt securities.

Global Diversified Allocation

Adopting a globally diversified approach to balance growth and defense, the fund pursues returns through large-cap growth stocks and high-yield bonds while enhancing defensive capabilities via investment-grade bonds and options. Credit quality is primarily concentrated in the BBB+ to BB range, with a duration of under 2 years to provide moderate interest rate and credit risk management.

Professional Management Team

The fund leverages the combined expertise of KGI Group and renowned asset manager Loomis Sayles to improve asset allocation precision and manage short-term volatility. Founded in 1926 and managing US\$425.5B in assets, Loomis Sayles identifies long-term value through rigorous research, risk control, and team collaboration.


Monthly Dividend Payout

The fund offers a monthly distribution share class with a target annualized payout rate of 8%.


Inception	2026/3/9	Currency	USD
Morningstar Category	Asset Allocation	Fund Type	Balanced
Morningstar Rating	-	3Y SD (Ann.)	-

Source: Bloomberg

Sectors



Asset




As of 14 Apr 2026	1M	3M	YTD	1Y	3Y	5Y
Cumulative Return(%)	3.90	-	3.90	-	-	-
Similar Fund Quartile Ranking	1	-	1	-	-	-

Top-5 Holdings (%)

Apple Inc.	3.3
NVIDIA Corp.	3.1
iShares 0-5 Year Investment Grade Corporate Bond ETF	3.0
Microsoft Corp.	3.0
Amazon.com, Inc.	2.9

NAV (Since Inception)



Trump Initiates Section 232 Tariffs on Pharmaceuticals, Benefiting US Pharma Companies

► State Street SPDR S&P Pharmaceuticals ETF (XPH)

- Designed to track the performance of the S&P Pharmaceuticals Select Industry Index.
- Utilizes an equal-weight strategy, covering U.S. pharmaceutical giants as well as small-and-mid-cap enterprises. This allows investors to participate in the stability of large-cap pharma and the explosive potential of mid-to-small-cap growth stocks.
- Diversified holdings: Individual stock weights are capped at approximately 2%, with the top 10 holdings accounting for only about 22% of the portfolio.

► iShares U.S. Pharmaceuticals ETF (IHE)

- Designed to track the performance of the Dow Jones U.S. Select Pharmaceuticals Index.
- Focuses on domestic U.S. pharmaceutical giants to capture industry growth momentum.
- Highly concentrated holdings: The top two positions, including traditional large-cap value stock Johnson & Johnson and growth stock Eli Lilly, represent about 43% of the portfolio. The portfolio also includes major players like Merck and Pfizer, providing a robust foundation for the fund.

Products	State Street SPDR S&P Pharmaceuticals ETF (XPH)	iShares U.S. Pharmaceuticals ETF (IHE)
Features	<ul style="list-style-type: none"> ■ Equal-weighted; top 10 holdings account for ~22% of portfolio. ■ High SMID-cap exposure; provides industry growth and diversification. 	<ul style="list-style-type: none"> ■ Market-cap weighted; focuses on large pharma with scale, global reach, and cash flow. ■ AUM near US\$1B; large scale for its peer group with good liquidity.
AUM	US\$349M	US\$956M
Tracking Index	S&P Pharmaceuticals Select Industry Index	Dow Jones U.S. Select Pharmaceuticals Index
Exchange	NYSE	NYSE
Currency	USD	USD
Holdings	59	56
Expense Ratio	0.35%	0.38%
3M/YTD Return	3.33% / 2.78%	2.30% / 3.32%
Sectors (%)	Pharmaceuticals 100	Pharmaceuticals 100
Holdings (%)	Organon & Co. 2.59 Intra-Cellular Therapies 2.58 Corcept Therapeutics 2.35 Trevi Therapeutics Inc 2.15 Definium Therapeutics 2.14	Johnson & Johnson 22.33 Eli Lilly & Co. 20.58 Royalty Pharma PLC 4.74 Merck & Co. 4.61 Zoetis Inc. 4.58

Source: Bloomberg

State Street SPDR S&P Pharmaceuticals ETF (XPH.US)

Profile

The ETF tracks the S&P Pharmaceuticals Select Industry Index, aiming to match the investment performance of its constituent stocks.

■ Equal-Weight Configuration

The tracked index employs an equal-weight rather than a market-cap-weighted approach. Consequently, the top 10 holdings account for only ~22% of the portfolio.

■ High SMID-Cap Exposure

With high weightings in R&D-focused, rare disease, and biopharma firms, small-to-mid-cap stocks represent over 80% of the fund. This makes it highly sensitive to catalysts such as FDA approvals, successful clinical trials, and M&A activity, offering both industry growth and diversification.

■ Competitive Fees

With an expense ratio of ~0.35%, it is lower than most pharmaceutical thematic ETFs, helping investors save on costs over the long term.


Inception	2000/6/19	AUM	US\$349M
ETF Type	Equities	Holdings	59
Exp. Ratio	0.35%	3Y SD (p.a.)	19.77%

Source: Bloomberg

Sectors



1-Year Price



As of 15 Apr 2026

Cumulative Return(%)

1M

3M

YTD

1Y

3Y

5Y

7.04

3.33

2.78

54.06


43.95

25.55

Top-5 Holdings (%)

Organon & Co.	2.59
Intra-Cellular Therapies	2.58
Corcept Therapeutics	2.35
Trevi Therapeutics Inc	2.15
Definium Therapeutics	2.14

Last 1-Year Volatility



iShares U.S. Pharmaceuticals ETF (IHE.US)

Profile

This ETF tracks the Dow Jones U.S. Select Pharmaceuticals Index, aiming to replicate the performance of its underlying components.

Market-Cap Weighted Design

The index follows a market-cap-weighted strategy, resulting in a portfolio highly concentrated in large-cap pharmaceutical giants with scale advantages, global distribution, and strong cash flows. The top two holdings, Johnson & Johnson and Eli Lilly, have a combined weighting of ~43%.

Pure U.S. Pharma Exposure


The fund invests exclusively in U.S.-listed pharmaceutical companies, excluding hospitals, insurance, or medical devices. It focuses strictly on FDA regulations, drug pricing policies, and the R&D ecosystem, offering high clarity and singular industry exposure.

Large Scale and High Liquidity

With an AUM near US\$1B, it is one of the largest ETFs in its category. Its excellent liquidity makes it suitable for larger capital allocations or tactical position adjustments.

Inception	2006/5/1	AUM	US\$956M
ETF Type	Equities	Holdings	56
Exp. Ratio	0.38%	3Y SD (p.a.)	15.85%

Sectors



1-Year Price




As of 15 Apr 2026	1M	3M	YTD	1Y	3Y	5Y
Cumulative Return(%)	0.62	2.30	3.32	43.75	52.06	59.71

Top-5 Holdings (%)

Johnson & Johnson	22.33
Eli Lilly & Co.	20.58
Royalty Pharma PLC	4.74
Merck & Co.	4.61
Zoetis Inc.	4.58

Last 1-Year Volatility



Source: Bloomberg

Enhancing Yield Through High-Quality Pharma Leader Bonds

- ▶ **MRK 4.45 12/04/2032 (Merck & Co.) (USD)**
- ▶ **MRK 4.75 12/04/2035 (Merck & Co.) (USD)**

- Merck & Co. is a global leading pharmaceutical company and a constituent of the Dow Jones Industrial Average. Its bonds are rated Aa3 by Moody's and A+ by S&P. The company focuses on the R&D, manufacturing, and marketing of pharmaceuticals and vaccines, alongside its animal health division. Its flagship oncology immunotherapy, Keytruda, achieved sales of US\$29.48 billion in 2024, an 18% increase (including FX impacts) compared to 2023.
- The pharmaceutical industry offers high entry barriers, strong pricing power, and low sensitivity to business cycle fluctuations. Merck's above-industry-average R&D investment supports sustained organic revenue growth. As of year-end 2024, its adjusted EBITDA margin stood at 38.58%, with a net debt/EBITDA ratio of 0.99x and a robust interest coverage ratio of 19.48x.
- The company maintains conservative credit metrics. S&P Global Ratings expects Merck to have ample room for mergers and acquisitions (M&A) under its current credit rating. Following the November 2024 announcement to acquire Cidara Therapeutics Inc., net leverage is expected to remain within the 1.5x to 2.0x range, supported by strong cash flow generation and the ongoing expansion of Keytruda's patent rights.
- The acquisition integrates Cidara's lead asset, CD388, into Merck's pipeline. CD388 is a single-dose, long-acting antiviral currently in clinical trials for the prevention of seasonal and pandemic influenza. Should Phase 3 trials demonstrate superior preventative efficacy, this asset has the potential to boost Merck's sales and further diversify the company's product portfolio risks.

Source: Bloomberg

Products	MRK 4.45 12/04/2032 (Merck & Co.) (USD)	MRK 4.75 12/04/2035 (Merck & Co.) (USD)
ISIN	US58933YBY05	US58933YBZ79
Features	Companies with above-industry-average R&D investment support sustained endogenous revenue growth.	
Maturity Date	2032/12/4	2035/12/4
Next Call Date	2032/10/4	2035/9/4
Coupon (%)	Fixed/4.45/Semi-Annual	Fixed/4.75/Semi-Annual
Currency	USD	USD
Years to Maturity	6.64	9.64
Credit Rating (Moody's/ Fitch/S&P)	Aa3/-/A+	Aa3/-/A+
Seniority	Senior Unsecured	Senior Unsecured
YTM/YTC (%)	4.32/4.32	4.75/4.75

Merck & Co. (MRK 4.45 12/04/2032)


Merck & Co. is a global leading pharmaceutical company and a constituent of the Dow Jones Industrial Average. Its bonds are rated Aa3 by Moody's and A+ by S&P. The company focuses on the R&D, manufacturing, and marketing of pharmaceuticals and vaccines, alongside its animal health division. Its flagship oncology immunotherapy, Keytruda, achieved sales of US\$29.48 billion in 2024, an 18% increase (including FX impacts) compared to 2023.

- Merck's above-industry-average R&D investment supports sustained organic revenue growth. As of year-end 2024, its adjusted EBITDA margin stood at 38.58%, with a net debt/EBITDA ratio of 0.99x and a robust interest coverage ratio of 19.48x.
- The company maintains conservative credit metrics. S&P Global Ratings expects Merck to have ample room for mergers and acquisitions (M&A) under its current credit rating. Following the November 2024 announcement to acquire Cidara Therapeutics Inc., net leverage is expected to remain within the 1.5x to 2.0x range, supported by strong cash flow generation and the ongoing expansion of Keytruda's patent rights.
- The acquisition integrates Cidara's lead asset, CD388, into Merck's pipeline. CD388 is a single-dose, long-acting antiviral currently in clinical trials for the prevention of seasonal and pandemic influenza. Should Phase 3 trials demonstrate superior preventative efficacy, this asset has the potential to boost Merck's sales and further diversify the company's product portfolio risks.

Financials	2023	2024	2025
Free Cash Flow (USD 100M)	91.43	180.96	123.60
EBITDA Margin (%)	10.92	38.58	42.27
Interest Coverage Ratio (x)	5.73	19.48	20.25

Source: Bloomberg

Overview			
Name	MRK 4.45 12/04/2032	ISIN	US58933YBY05
Maturity Date	2032/12/4	Remaining Maturity	6.64
Coupon(%)	Fixed/4.45/Semi-Annual	YTM/YTC(%)	4.32/4.32
Currency	USD	Min. Subscription/ Increment	2,000/1,000
Ratings (Moody's/Fitch/S&P)	Aa3/-/A+	Seniority	Senior Unsecured



Merck & Co. (MRK 4.75 12/04/2035)


Merck & Co. is a global leading pharmaceutical company and a constituent of the Dow Jones Industrial Average. Its bonds are rated Aa3 by Moody's and A+ by S&P. The company focuses on the R&D, manufacturing, and marketing of pharmaceuticals and vaccines, alongside its animal health division. Its flagship oncology immunotherapy, Keytruda, achieved sales of US\$29.48 billion in 2024, an 18% increase (including FX impacts) compared to 2023.

- Merck's above-industry-average R&D investment supports sustained organic revenue growth. As of year-end 2024, its adjusted EBITDA margin stood at 38.58%, with a net debt/EBITDA ratio of 0.99x and a robust interest coverage ratio of 19.48x.
- The company maintains conservative credit metrics. S&P Global Ratings expects Merck to have ample room for mergers and acquisitions (M&A) under its current credit rating. Following the November 2024 announcement to acquire Cidara Therapeutics Inc., net leverage is expected to remain within the 1.5x to 2.0x range, supported by strong cash flow generation and the ongoing expansion of Keytruda's patent rights.
- The acquisition integrates Cidara's lead asset, CD388, into Merck's pipeline. CD388 is a single-dose, long-acting antiviral currently in clinical trials for the prevention of seasonal and pandemic influenza. Should Phase 3 trials demonstrate superior preventative efficacy, this asset has the potential to boost Merck's sales and further diversify the company's product portfolio risks.

Financials	2023	2024	2025
Free Cash Flow (USD 100M)	91.43	180.96	123.60
EBITDA Margin (%)	10.92	38.58	42.27
Interest Coverage Ratio (x)	5.73	19.48	20.25

Source: Bloomberg

Overview			
Name	MRK 4.75 12/04/2035	ISIN	US58933YBZ79
Maturity Date	2035/12/4	Remaining Maturity	9.64
Coupon(%)	Fixed/4.75/Semi-Annual	YTM/YTC(%)	4.75/4.75
Currency	USD	Min. Subscription/ Increment	2,000/1,000
Ratings (Moody's/Fitch/S&P)	Aa3/-/A+	Seniority	Senior Unsecured



Goldman Sachs Delivers Stellar 2025 Performance; Solid Momentum Heading into 2026

► GS 5.094 04/20/34 (Goldman Sachs Group, Inc.) (USD)

- The Goldman Sachs Group, Inc., with a history spanning over a century, is one of the world's most influential investment banking and financial services institutions. Its core businesses encompass investment banking, asset management, wealth management, and emerging fintech platforms, serving governments, multinational corporations, institutional investors, and high-net-worth clients.
- Investment Banking Continues to Drive Revenue Growth: Investment banking fees surged 48% YoY to US\$2.84B. Advisory fees were particularly standout, increasing 89% YoY to US\$1.49B. Equity Capital Markets (ECM) revenue grew 45% YoY, while debt underwriting revenue rose 8% YoY, demonstrating robust growth momentum.
- Steady Growth in Asset & Wealth Management: Segment revenue reached US\$4.08B this quarter, up 10% YoY, primarily benefiting from rising asset prices and sustained positive long-term net inflows. Management fees increased 14% YoY, reflecting the expansion of AUM and improved portfolio performance.
- Stellar Financial Performance: For the 2025 fiscal year, the company recorded revenue of US\$58.28B, up 9% YoY, with net income reaching US\$17.18B. Its Common Equity Tier 1 (CET1) ratio stood at 14.30%, well above the regulatory requirement of 11.40%, indicating a robust level of capital adequacy and risk-bearing capacity.
- Stable Credit Rating Outlook: The company maintains a stable outlook from major credit rating agencies (Moody's, S&P, Fitch). This stable outlook reflects the company's strong balance sheet and its solid performance across global banking and markets.

Products	GS 5.094 04/20/34 (Goldman Sachs Group, Inc.) (USD)
ISIN	US38141GF251
Features	The company's investment banking, asset management, and wealth management businesses are experiencing steady growth, and its credit rating outlook remains stable.
Maturity Date	2034/4/20
Next Call Date	2033/4/20
Coupon (%)	Float/5.094/Semi-Annual
Currency	USD
Years to Maturity	8.01
Credit Rating (Moody's/Fitch/S&P)	-/A/BBB+
Seniority	Senior Unsecured
YTM/YTC (%)	4.95/4.94

Source: Bloomberg

Goldman Sachs Group, Inc. (GS 5.094 04/20/34)


The Goldman Sachs Group, Inc., with a history spanning over a century, is one of the world's most influential investment banking and financial services institutions. Its core businesses encompass investment banking, asset management, wealth management, and emerging fintech platforms, serving governments, multinational corporations, institutional investors, and high-net-worth clients.

- **Investment Banking Continues to Drive Revenue Growth:** Investment banking fees surged 48% YoY to US\$2.84B. Advisory fees were particularly standout, increasing 89% YoY to US\$1.49B. Equity Capital Markets (ECM) revenue grew 45% YoY, while debt underwriting revenue rose 8% YoY, demonstrating robust growth momentum.
- **Steady Growth in Asset & Wealth Management:** Segment revenue reached US\$4.08B this quarter, up 10% YoY, primarily benefiting from rising asset prices and sustained positive long-term net inflows. Management fees increased 14% YoY, reflecting the expansion of AUM and improved portfolio performance.
- **Stellar Financial Performance:** For the 2025 fiscal year, the company recorded revenue of US\$58.28B, up 9% YoY, with net income reaching US\$17.18B. Its Common Equity Tier 1 (CET1) ratio stood at 14.30%, well above the regulatory requirement of 11.40%, indicating a robust level of capital adequacy and risk-bearing capacity.

Financials	2023	2024	2025
CET1 ratio (%)	14.50	15.00	14.30
EBITDA Margin (%)	72.17	74.58	73.00
Liquidity Coverage Ratio (%)	128.00	126.00	123.00

Source: Bloomberg

Overview			
Name	GS 5.094 04/20/34	ISIN	US38141GF251
Maturity Date	2033/4/20	Remaining Maturity	8.01
Coupon(%)	Float/5.094/Semi-Annual	YTM/YTC(%)	4.95/4.94
Currency	USD	Min. Subscription/ Increment	1,000/1,000
Ratings (Moody's/Fitch/S&P)	-/A/BBB+	Seniority	Senior Unsecured



Appendix

Key Economic Data / Events

► APR 2026

13

Monday

- U.S. Mar Existing Home Sales (Act:3.98m Est:4.05m Prev:4.13m)

14

Tuesday

- U.S. Mar PPI YoY (Act:4.0% Est:4.6% Prev:3.4%)
- Japan Feb Industrial Production MoM (Final) (Act:-2.0% Prev:4.3%)

15

Wednesday

- Japan Feb Core Machine Orders MoM (Act:13.6% Est:-1.1% Prev:-5.5%)
- Eurozone Feb Industrial Production MoM (Act:0.4% Est:0.3% Prev:-0.8%)

16

Thursday

- U.S. Weekly Initial Jobless Claims (Act:207k Est:213k Prev:218k)
- China Q1 GDP YoY (Act:5.0% Est:4.8% Prev:4.5%)
- China Mar Retail Sales YoY (Act:1.7% Est:2.4% Prev:2.8%)
- China Mar Industrial Production YoY (Act:5.7% Est:5.3% Prev:6.3%)
- Eurozone Mar CPI YoY (Final) (Act:2.6% Est:2.5% Prev:1.9%)

17

Friday

20

Monday

21

Tuesday

- U.S. Mar Retail Sales MoM (Est:1.3% Prev:0.6%)
- Taiwan Mar Export Orders YoY (Est:38.5% Prev:23.8%)
- Earnings: GE, UNH, RTX, DHR

22

Wednesday

- Eurozone Apr Consumer Confidence (prelim) (Prev:-16.3)
- Earnings: IBKR, COF, ISRG, CB, GEV, PM, T, BA, TXN

23

Thursday

- U.S. Weekly Initial Jobless Claims (Est:210k Prev:207k)
- U.S. Apr S&P Global Manufacturing PMI (prelim) (Est:52.8 Prev:52.3)
- Japan Apr S&P Global Manufacturing PMI (prelim) (Prev:51.6)
- Eurozone Apr S&P Global Manufacturing PMI (prelim) (Prev:51.6)
- Earnings: TSLA, LRCX, IBM, LMT, AXP, NEE, UNP

24

Friday

- U.S. Apr Univ. of Michigan Consumer Sentiment (Final) (Est:48.3 Prev:53.3)
- Japan Mar National CPI YoY (Est:1.5% Prev:1.3%)
- Earnings: INTC, NEM

Source: Bloomberg

For Internal Use Only

29


Key Earnings Releases

Date	Name	Revenue (F) (USD)	Actual Revenue (USD)	EPS (F) (USD)	Actual EPS (USD)	Exceed Expectation	
						Revenue	EPS
2026/4/13	Goldman Sachs (GS)	16.95B	17.23B	16.34	17.55	V	V
2026/4/14	BlackRock (BLK)	6.5B	6.7B	11.48	12.53	V	V
2026/4/14	JPMorgan Chase (JPM)	49.26B	50.54B	5.41	5.94	V	V
2026/4/14	Johnson & Johnson (JNJ)	23.66B	24.06B	2.69	2.7	V	V
2026/4/14	Wells Fargo (WFC)	21.76B	21.45B	1.58	1.56		
2026/4/14	Citigroup (C)	23.54B	24.6B	2.66	3.06	V	V
2026/4/15	Progressive (PGR)	22.02B	22.19B	4.84	4.96	V	V
2026/4/15	Bank of America (BAC)	30.02B	30.27B	1.01	1.11	V	V
2026/4/15	Morgan Stanley (MS)	19.71B	20.58B	2.98	3.43	V	V
2026/4/16	PepsiCo (PEP)	18.93B	19.44B	1.55	1.61	V	V
2026/4/16	Abbott Laboratories (ABT)	11.01B	11.16B	1.15	1.15	V	
2026/4/16	Charles Schwab (SCHW)	6.51B	6.48B	1.39	1.43		V
2026/4/16	Prologis (PLD)	2.27B	2.3B	1.49	1.5	V	V
2026/4/17	Netflix (NFLX)	12.17B	12.25B	0.76	1.23	V	V


Source: Investing.com

Major Market / Asset YTD Performance

Equities & Bond Markets YTD Performance (%)








Currencies and Commodities Market YTD Performance (%)



Source: Bloomberg


Technical Analysis




Source: Bloomberg

Market Monitor

U.S. CPI YoY (%)




U.S. 10-Year Treasury Yield (%)




U.S. Treasury Yield Spread (bps)




U.S. Treasury Yield Curve (%)




USD IG Credit Spread (%)




USD HY Credit Spread (%)



USD EM Credit Spread (%)




USD Asia Credit Spread (%)




Source: Bloomberg

Market Monitor


VIX Index




VIX Term Structure




U.S. Citi Economic Surprise Index*




U.S. Citi Inflation Surprise Index*




TED Spread (bps)




U.S. Dollar Index



EUR to USD



USD to JPY



Source: Bloomberg



Disclaimer and Important Notice

Hong Kong: The information contained in the document herein is confidential and is not intended for general public distribution or for use by any person or entity located or residing in any jurisdiction which restricts the distribution of such information by KGI Asia Limited ("KGI") or any affiliate of KGI. Re-distribution of the document herein and any part thereof by any means is strictly prohibited. Such information shall not be regarded as an offer, invitation, solicitation or recommendation to invest in or sell any securities or investment products to any person or entity in any jurisdiction. The above information (including but not limited to general financial and market information, news services, market analysis and product information) is for general information and reference purpose only and may not be reproduced or published (in whole or in part) for any purpose without the prior written consent of KGI Asia Ltd. Such information is not intended to provide investment advice and should not be relied upon in that regard. You are advised to exercise caution, and if you are in any doubt about such information, you should seek independent professional advice.

You are advised to exercise caution and undertake your own independent review, and you should seek independent professional advice before making any investment decision. You should carefully consider whether investment is suitable in light of your own risk tolerance, financial situation, investment experience, investment objectives, investment horizon and investment knowledge.

No representation or warranty is given, whether express or implied, on the accuracy, adequacy or completeness of information provided herein. In all cases, anyone proposing to rely on or use the information contained herein should independently verify and check the accuracy, completeness, reliability and suitability of the information. Simulations, past and projected performance may not necessarily be indicative of future results. Information including the figures stated herein may not necessarily have been independently verified, and such information should not be relied upon in making investment decisions. None of KGI, its affiliates or their respective directors, officers, employees and representatives will be liable for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind) suffered or incurred by any person or entity due to any omission, error, inaccuracy, incompleteness or otherwise, or any reliance on such information. Furthermore, none of KGI, its affiliates or their respective directors, officers, employees and representatives shall be liable for the content of information provided by or quoted from third parties.

Complex Products refers to an investment product whose terms, features and risks are not reasonably likely to be understood by a retail investor because of its complex structure. Investors should exercise caution in relation to complex products. Investors may lose the entire amount or more than the invested amount. For complex products with offering documents or information not reviewed by the Hong Kong Securities and Futures Commission (SFC), investors should exercise caution regarding the offer. For complex products described as SFC-approved, such approval does not imply official endorsement, and SFC recognition does not equate to a recommendation or assurance of the product's commercial viability or performance. Past performance data, if provided, is not indicative of future performance. Some complex products are only available to professional investors. Before making any investment decisions, investors should review the offering documents and other relevant information to understand the key nature, features, and risks of the complex products. Independent professional advice should be sought, and investors should have sufficient net assets to bear the potential risks and losses associated with the product. Members of the KGI group and their affiliates may provide services to any companies and affiliates of such companies mentioned herein. Members of the KGI group, their affiliates and their directors, officers, employees and representatives may from time to time have a position in any securities mentioned herein.

Bond investment is NOT equivalent to a time deposit. It is NOT protected under the Hong Kong Deposit Protection Scheme. Bondholders are exposed to a variety of risks, including but not limited to: (i) Credit risk - The issuer is responsible for payment of interest and repayment of principal of bonds. If the issuer defaults, the holder of bonds may not be able to receive interest and get back the principal. It should also be noted that credit ratings assigned by credit rating agencies do not guarantee the creditworthiness of the issuer; (ii) Liquidity risk - some bonds may not have active secondary markets and it would be difficult or impossible for investors to sell the bond before its maturity; (iii) Interest rate risk – When the interest rate rises, the price of a fixed rate bond will normally drop, and vice versa. If you want to sell your bond before it matures, you may get less than your purchase price. Do not invest in bond unless you fully understand and are willing to assume the risks associated with it. Please seek independent advice if you are unsure.

All investments involve risks. The prices of securities fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. Prices of securities and fund units may go up as well as down and past performance information presented is not indicative of future performance. Investors should read the relevant fund's offering documents (including the full text of the risk factors stated therein (in particular those associated with investments in emerging markets for funds investing in emerging markets)) in detail before making any investment decision. You are advised to exercise caution and undertake your own independent review, and you should seek independent professional advice before making any investment decision. You should carefully consider whether investment is suitable in light of your own risk tolerance, financial situation, investment experience, investment objectives, investment horizon and investment knowledge.

Singapore: This document is provided for general information and circulation only, and is not an offer or a solicitation to deal in any securities or to enter into any legal relations, nor an advice or a recommendation with respect to any financial products mentioned herein. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. You should ensure that you understand the risk(s) involved and should independently evaluate particular investments and consult an independent financial adviser before making any investment decisions. All information and opinions contained herein is based on certain assumptions, information and conditions available as at the date of this document and may be subject to change at any time without notice.